Clinical Trial Detail

NCT ID NCT03775486
Title Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Olaparib

Cisplatin + Durvalumab + Pemetrexed Disodium

Durvalumab

Carboplatin + Durvalumab + Gemcitabine

Carboplatin + Durvalumab + Pemetrexed Disodium

Carboplatin + Durvalumab + Nab-paclitaxel

Cisplatin + Durvalumab + Gemcitabine

Age Groups: adult senior

Additional content available in CKB BOOST